More about

Chronic Spontaneous Urticaria

News
September 08, 2022
1 min read
Save

Remibrutinib safety profile continues with long term use for chronic spontaneous urticaria

Remibrutinib safety profile continues with long term use for chronic spontaneous urticaria

MILAN — Long term use of remibrutinib was safe and well tolerated for patients with chronic spontaneous urticaria, according to a poster presented at the European Academy of Dermatology and Venereology Congress.

News
August 22, 2022
2 min read
Save

Scratching provides high pleasure for patients with chronic spontaneous urticaria

Scratching provides high pleasure for patients with chronic spontaneous urticaria

Patients with chronic spontaneous urticaria experience more pleasure from scratching itches compared with patients with other skin conditions, according to a study published in The Journal of Allergy and Clinical Immunology: In Practice.

News
July 06, 2022
3 min read
Save

Remibrutinib reduces rescue medication use among adults with chronic spontaneous urticaria

Remibrutinib reduces rescue medication use among adults with chronic spontaneous urticaria

Remibrutinib reduced the need for rescue medication and improved symptoms among patients with chronic spontaneous urticaria, according to a study presented at the European Academy of Allergy and Clinical Immunology Hybrid Congress.

News
April 28, 2022
3 min read
Save

Patients with idiopathic angioedema show improvement with omalizumab

Patients with idiopathic angioedema show improvement with omalizumab

Patients with chronic spontaneous urticaria demonstrated improved outcomes related to idiopathic angioedema after taking omalizumab, according to a study presented at the American Academy of Allergy, Asthma & Immunology Annual Meeting.

News
April 14, 2022
3 min read
Save

Ligelizumab improves sleep among patients with chronic spontaneous urticaria

Ligelizumab improves sleep among patients with chronic spontaneous urticaria

Patients with chronic spontaneous urticaria who used ligelizumab reported improvements in their sleep quality compared with patients who received omalizumab or placebo, according to a study published in Clinical and Translational Allergy.

News
March 26, 2022
1 min read
Save

Chronic spontaneous urticaria negatively impacts life, work

BOSTON — Chronic spontaneous urticaria has a negative impact on patients’ lives, including on both mental and physical health and daily activities, according to a poster presented at the American Academy of Dermatology Annual Meeting.

News
March 02, 2022
2 min read
Save

Dupilumab relieves chronic spontaneous urticaria symptoms

Dupilumab relieves chronic spontaneous urticaria symptoms

PHOENIX — Patients with H1 antihistamine-resistant chronic spontaneous urticaria experienced improvements with dupilumab, according to a study presented at the American Academy of Allergy, Asthma & Immunology Annual Meeting.

News
October 04, 2021
1 min read
Save

Chronic spontaneous urticaria improvement seen with remibrutinib

Remibrutinib provided significant improvement in chronic spontaneous urticaria in a phase 2b dose affirming trial presented at the EADV virtual congress.

News
September 07, 2021
2 min read
Save

Ligelizumab, omalizumab most effective in refractory chronic spontaneous urticaria

Ligelizumab and omalizumab were found to be the most effective treatments for adolescent and adult patients with chronic spontaneous urticaria who had failed to respond to H1 antihistamines, according to a study.

News
July 29, 2021
1 min read
Save

Dupixent improves itch, hives in phase 3 chronic spontaneous urticaria trial

Dupixent reduced both itch and hives in patients with moderate to severe chronic spontaneous urticaria in a pivotal phase 3 trial, Regeneron and Sanofi announced in a press release.

View more